Boston Scientific's soon-to-be-departing chief financial officer has sold off nearly 600,000 shares in November on his way out the door, bringing nearly $7 million, and a number of other senior executives also unloaded hundreds of thousands of shares. Some observers see the move as a predictor of more measured longer-term prospects for the rebounding company.
Boston Scientific won FDA approval for yet another next-generation drug-eluting coronary stent system and has immediately ramped up its marketing machine to pursue new sales.
Beyond layoffs and acquisitions, Boston Scientific continues to advance new products through global regulatory approvals in an ongoing effort to restore robust revenue growth. The latest entry is a new microcatheter, which now has FDA clearance in the U.S. and a CE mark in Europe.
Boston Scientific's Vercise deep brain stimulation system isn't yet approved in the U.S., but it continues to rack up regulatory blessings overseas. In the latest advance, the product now has a CE mark to treat a neurological movement disorder known as dystonia.
Boston Scientific is ticking closer to judgment day for its much-scrutinized Watchman device, securing an FDA advisory hearing for a stroke-fighting implant that has faced doubts throughout its development.
Israel's Sensible Medical has picked up a reported $20 million to fund development of its noninvasive lung fluid monitor, closing a round led by global device giant Boston Scientific.
Medtronic's ongoing patent fight with Boston Scientific over the use of cardiac device tech finally had its day before the U.S. Supreme Court on Nov. 5. Now comes the waiting. Reuters reported that a ruling in the matter is expected by the end of June 2014.
Medtronic's long-running patent fight with Boston Scientific over the use of cardiac device tech finally goes before the U.S. Supreme Court on Nov. 5, the culmination of a battle that has carried on for years.
It took close to 5 months, but Boston Scientific has closed its $275 million bid for C.R. Bard's electrophysiology business, which will help in its continued fight to rebound and return to robust revenue growth.
Boston Scientific, the latest entrant into the transcatheter valve replacement space, has won a CE mark for its Lotus implant, nudging the company into an overseas market headlined by squabbles between Edwards Lifesciences and Medtronic.